These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27696791)

  • 1. Defining Low Disease Activity in Systemic Lupus Erythematosus.
    Polachek A; Gladman DD; Su J; Urowitz MB
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):997-1003. PubMed ID: 27696791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
    Sato JO; Corrente JE; Saad-Magalhães C
    Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
    Pakchotanon R; Gladman DD; Su J; Urowitz MB
    J Rheumatol; 2018 Jan; 45(1):90-94. PubMed ID: 29142038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
    Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Barber MRW; Ugarte-Gil MF; Hanly JG; Urowitz MB; St-Pierre Y; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Pons-Estel BA; Cardwell FS; Alarcón GS; Clarke AE
    Ann Rheum Dis; 2024 Sep; 83(10):1295-1303. PubMed ID: 38754981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
    Urowitz MB; Gladman DD; Ibañez D; Su J; Mursleen S; Sayani A; Ross Terres JA; Iczkovitz S
    J Rheumatol; 2021 Jan; 48(1):67-73. PubMed ID: 32238510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis.
    Maloney KC; Ferguson TS; Stewart HD; Myers AA; De Ceulaer K
    Lupus; 2017 Nov; 26(13):1448-1456. PubMed ID: 28480787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients-a multicenter retrospective cohort.
    Medhat BM; Behiry ME; Sobhy N; Farag Y; Marzouk H; Mostafa N; Khalifa I; Elkhalifa M; Eissa BM; Hassan EHE
    Clin Rheumatol; 2020 Feb; 39(2):435-442. PubMed ID: 31758421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus.
    Peschken CA; Wang Y; Abrahamowicz M; Pope J; Silverman E; Sayani A; Iczkovitz S; Ross J; Zummer M; Tucker L; Pineau C; Levy D; Hudson M; Hitchon CA; Huber AM; Smith CD; Avina-Zubieta A; Arbillaga H; Chédeville G; Wynant W; Fortin PR;
    J Rheumatol; 2019 Feb; 46(2):166-175. PubMed ID: 30219771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years.
    Taraborelli M; Cavazzana I; Martinazzi N; Lazzaroni MG; Fredi M; Andreoli L; Franceschini F; Tincani A
    Lupus; 2017 Oct; 26(11):1197-1204. PubMed ID: 28420047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.